Related Experiment Video
Updated: May 7, 2026
03:37
Intravitreal Injections in the Ovine Eye
Published on: July 5, 2022
[VEGF inhibitors in vitreoretinal interventions].
1Universitäts-Augenklinik, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland, nicolas.feltgen@med.uni-goettingen.de.
Summary
Vascular endothelial growth factor (VEGF) inhibitors are increasingly used in ophthalmology. While beneficial, they carry risks like tractional retinal detachment if proliferative membranes are overlooked during vitreoretinal surgery.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Medical Treatments
Context:
- Vascular endothelial growth factor (VEGF) inhibitors are expanding therapeutic applications beyond exudative macular degeneration.
- Off-label uses include adjunctive treatment with panretinal laser photocoagulation and pre-operative preparation for vitrectomy in ischemic retinopathy.
Purpose:
- To review the current understanding of VEGF inhibition as an adjunct to vitreoretinal surgery.
- To identify knowledge gaps and areas requiring further research in this therapeutic approach.
Summary:
- VEGF inhibitors are frequently administered before vitreoretinal surgery or alongside laser photocoagulation.
- Anti-VEGF therapy does not typically replace the need for laser coagulation.
- A significant risk involves misjudging or overlooking proliferative membranes, potentially leading to contraction and tractional retinal detachment.
Impact:
- Highlights the critical importance of accurate assessment of proliferative membranes when using anti-VEGF agents.
- Underscores the need for further research to optimize the use of VEGF inhibitors in complex retinal conditions.
- Informs clinical practice regarding the benefits and potential hazards of VEGF inhibition in vitreoretinal surgery.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...